Osteogenesis Imperfecta: Maintenance of Adult Bone Health - Osteogenesis Imperfecta - page 472

[12] Chen CJ, Chao TY, Janckila AJ, Cheng SN, Ku CH, Chu DM.

Evaluation of the activity of tartrate-resistant acid phosphatase
isoform 5b in normal Chinese children - a novel marker for
bone growth. J Pediatr Endocrinol Metab 2005;18(1):55-62.

[30] Yoshihara A, Deguchi T, Hanada N, Miyazaki H. Relation

of bone turnover markers to periodontal disease and jaw
bone morphology in elderly Japanese subjects. Oral Dis
2009;15(2):176-81.

[13] Crofton PM, Evans N, Taylor MR, Holland CV. Serum

CrossLaps: pediatric reference intervals from birth to 19 years of
age. Clin Chem 2002;48(4):671-3.

[31] Vlasiadis KZ, Damilakis J, Velegrakis GA, Skouteris CA,

Fragouli I, Goumenou A, et al. Relationship between BMD,
dental panoramic radiographic indings and biochemical mark-
ers of bone turnover in diagnosis of osteoporosis. Maturitas
2008;59(3):226-33.

[14] Kubo T, Tanaka H, Inoue M, Kanzaki S, Seino Y. Serum levels

of carboxyterminal propeptide of type I procollagen and pyridi-
noline crosslinked telopeptide of type I collagen in normal chil-
dren and children with growth hormone (GH) deiciency during
GH therapy. Bone 1995;17(4):397-401.

[32] Peris P, Martínez-Ferrer A, Monegal A, Martínez de Osaba MJ,

Muxi A, Guañabens N. 25 hydroxyvitamin D serum levels inlu-
ence adequate response to bisphosphonate treatment in post-
menopausal osteoporosis. Bone 2012;51(1):54-8. [15] Tobiume H, Kanzaki S, Hida S, Ono T, Moriwake T, Yamauchi S,

et al. Serum bone alkaline phosphatase isoenzyme levels in
normal children and children with growth hormone (GH) dei-
ciency: a potential marker for bone formation and response to
GH therapy. J Clin Endocrinol Metab 1997;82(7):2056-61.

[33] Carmel AS, Shieh A, Bang H, Bockman RS. The 25(OH)D level

needed to maintain a favorable bisphosphonate response is
≥33 ng/ml. Osteoporos Int 2012;23(10):2479-87.

[34] Ross AC, Taylor CL, Yaktine AL, Del Valle HB. Dietary

Reference Intakes for Calcium and Vitamin D. Institute of
Medicine (US) Committee to Review Dietary Reference Intakes
for Vitamin D and Calcium. Washington (DC): National
Academies Press (US); 2011.

[16] Tsai KS, Jang MH, Hsu SH, Cheng WC, Chang MH. Bone alka-

line phosphatase isoenzyme and carboxy-terminal propeptide
of type-I procollagen in healthy Chinese girls and boys. Clin
Chem 1999;41(5):136-8.

[17] Aström E, Magnusson P, Eksborg S, Söderhäll S. Biochemical

bone markers in the assessment and pamidronate treatment of
children and adolescents with osteogenesis imperfecta. Acta
Paediatr 2010;99(12):1934-40.

[35] Cheung MS, Glorieux FH. Osteogenesis imperfecta: update

on presentation and management. Rev Endocr Metab Disord
2008;9(2):153-60.

[36] Ward LM, Rauch F, Whyte MP, D'Astous J, Gates PE,

Grogan D, et al. Alendronate for the treatment of pediatric
osteogenesis imperfecta: a randomized placebo-controlled
study. J Clin Endocrinol Metab 2011;96(2):355-64.

[18] Braga V, Gatti D, Rossini M, Colapietro F, Battaglia E,

Viapiana O, et al. Bone turnover markers in patients with osteo-
genesis imperfecta. Bone 2004;34(6):1013-6.

[19] Garnero P, Schott AM, Prockop D, Chevrel G. Bone turnover

and type I collagen C-telopeptide isomerization in adult osteo-
genesis imperfecta: associations with collagen gene mutations.
Bone 2009;44(3):461-6.

[37] Rauch F, Munns CF, Land C, Cheung M, Glorieux FH.

Risedronate in the treatment of mild pediatric osteogenesis
imperfecta: a randomized placebo-controlled study. J Bone
Miner Res 2009;24(7):1282-9.

[20] Cepollaro C, Gonnelli S, Pondrelli C, Montagnani A, Martini

S, Bruni D, et al. Osteogenesis imperfecta: bone turnover,
bone density, and ultrasound parameters. Calcif Tissue Int
1999;65(2):129-32.

[38] Shapiro JR, Germain-Lee EL. Osteogenesis imperfecta: effect-

ing the transition from adolescent to adult medical care. J
Musculoskelet Neuronal Interact 2012;12(1):24-7.

[39] Chevrel G, Schott AM, Fontanges E, Charrin JE,

Lina-Granade G, Duboeuf F, et al. Effects of oral alendro-
nate on BMD in adult patients with osteogenesis imperfecta: a
3-year randomized placebo-controlled trial. J Bone Miner Res
2006;21(2):300-6.

[21] Cundy T, Horne A, Bolland M, Gamble G, Davidson J. Bone for-

mation markers in adults with mild osteogenesis imperfecta.
Clin Chem 2007;53(6):1109-14.

[22] Lund AM, Hansen M, Kollerup G, Juul A, Teisner B, Skovby F.

Collagen-derived markers of bone metabolism in osteogenesis
imperfecta. Acta Paediatr 1998;87(11):1131-7.

[40] Adami S, Gatti D, Colapietro F, Fracassi E, Braga V, Rossini M,

et al. Intravenous neridronate in adults with osteogenesis
imperfecta. J Bone Miner Res 2003;18(1):126-30. [23] Shapiro JR. Comments. J Bone Miner Res 1995;10:338-9.

[24] Brenner RE, Schiller B, Vetter U, Ittner J, Teller WM. Serum con-

centrations of procollagen I C-terminal propeptide, osteocal-
cin and insulin-like growth factor-I in patients with non-lethal
osteogenesis imperfecta. Acta Paediatr 1993;82(9):764-7.

[41] Pavón de Paz I, Iglesias Bolaños P, Durán Martínez M, Olivar

Roldán J, Guijarro De Armas G, Parra García JI. Effects of zole-
dronic acid in adults with osteogenesis imperfecta. Endocrinol
Nutr 2010;57(6):245-50.

[25] Minisola S, Piccioni AL, Rosso R, Romagnoli E, Pacitti MT,

Scarnecchia L, et al. Reduced serum levels of carboxy-terminal
propeptide of human type I procollagen in a family with type
I-A osteogenesis imperfecta. Metabolism 1994;43(10):1261-5.

[42] Cranney A, Wells G, Willan A, Grifith L, Zytaruk N,

Robinson V, et al. Osteoporosis Methodology Group and the
Osteoporosis Research Advisory Group. Meta-analyses of thera-
pies for postmenopausal osteoporosis. II. Meta-analysis of alen-
dronate for the treatment of postmenopausal women. Endocr
Rev 2002;23(4):508-16.

[26] Prószy´ ska K, Wieczorek E, Olszaniecka M, Lorenc RS.

Collagen peptides in osteogenesis imperfecta, idiopathic juve-
nile osteoporosis and Ehlers-Danlos syndrome. Acta Paediatr
1996;85(6):688-91.

[43] Shapiro JR, Thompson CB, Wu Y, Nunes M, Gillen C. Bone min-

eral density and fracture rate in response to intravenous and
oral bisphosphonates in adult osteogenesis imperfecta. Calcif
Tissue Int 2010;87(2):120-9.

[27] Wekre LL, Eriksen EF, Falch JA. Bone mass, bone markers and

prevalence of fractures in adults with osteogenesis imperfecta.
Arch Osteoporos 2011;6(1-2):31-8. [44] Bradbury LA, Barlow S, Geoghegan F, Hannon RA, Stuckey SL,

Wass JA, et al. Risedronate in adults with osteogenesis imper-
fecta type I: increased bone mineral density and decreased
bone turnover, but high fracture rate persists. Osteoporos Int
2012;23(1):285-94.

[28] Ebetino FH, Hogan AM, Sun S, Tsoumpra MK, Duan X,

Trifitt JT, et al. The relationship between the chemistry and
biological activity of the bisphosphonates. Bone

2011;49(1):20-33.

[29] Taguchi A, Sanada M, Krall E, Nakamoto T, Ohtsuka M, Suei Y,

et al. Relationship between dental panoramic radiographic ind-
ings and biochemical markers of bone turnover. J Bone Miner
Res 2003;18(9):1689-94.

[45] Costa AG, Bilezikian JP. Sclerostin: therapeutic horizons based

upon its actions. Curr Osteoporos Rep 2012;10(1):64-72.

[46] Bellido T, Saini V, Pajevic PD. Effects of PTH on osteocyte func-

tion. Bone 2013;54(2):250-7.